ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
ProQR Therapeutics NV

ProQR Therapeutics NV (PRQR)

1.71
0.00
(0.00%)
Closed June 22 4:00PM
1.71
0.00
(0.00%)
After Hours: 6:20PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
1.71
Bid
1.61
Ask
5.00
Volume
43,478
1.68 Day's Range 1.7299
1.11 52 Week Range 3.29
Market Cap
Previous Close
1.71
Open
1.70
Last Trade
7
@
1.74
Last Trade Time
Financial Volume
$ 74,256
VWAP
1.7079
Average Volume (3m)
124,238
Shares Outstanding
81,354,592
Dividend Yield
-
PE Ratio
-4.95
Earnings Per Share (EPS)
-0.35
Revenue
6.59M
Net Profit
-28.12M

About ProQR Therapeutics NV

ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa. ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Leiden, South Holland, Nld
Founded
1970
ProQR Therapeutics NV is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker PRQR. The last closing price for ProQR Therapeutics NV was $1.71. Over the last year, ProQR Therapeutics NV shares have traded in a share price range of $ 1.11 to $ 3.29.

ProQR Therapeutics NV currently has 81,354,592 shares outstanding. The market capitalization of ProQR Therapeutics NV is $139.12 million. ProQR Therapeutics NV has a price to earnings ratio (PE ratio) of -4.95.

PRQR Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.07-3.932584269661.781.851.611705741.71171261CS
4-0.19-101.92.11.611063371.81747469CS
12-0.55-24.33628318582.262.461.611242381.98309733CS
26-0.31-15.34653465352.023.291.612185732.17866311CS
52-0.04-2.285714285711.753.291.112160211.86866667CS
156-6.1-78.1049935987.819.090.537844742.67534084CS
260-8.45-83.169291338610.1610.980.537439064.46988213CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AREBAmerican Rebel Holdings Inc
$ 0.76
(152.49%)
371.46M
SHCRSharecare Inc
$ 1.365
(76.27%)
56.33M
NXLNexalin Technologies Inc
$ 1.7499
(59.08%)
57.58M
FUFUBitFuFu Inc
$ 6.1209
(56.95%)
2.5M
SPECSpectaire Holdings Inc
$ 0.50
(47.06%)
65.27M
FLFVFeutune Light Acquisition Corporation
$ 2.5502
(-69.75%)
862.38k
FLFVUFeutune Light Acquisition Corporation
$ 2.75
(-66.83%)
16.5k
RWODRedwoods Acquisition Corporation
$ 2.34
(-60.34%)
155.96k
KAVLKaival Brands Innovations Group Inc
$ 1.23
(-57.14%)
4.92M
RWODURedwoods Acquisition Corporation
$ 3.24
(-56.28%)
1.47k
NVDANVIDIA Corporation
$ 126.57
(-3.22%)
658.13M
AREBAmerican Rebel Holdings Inc
$ 0.76
(152.49%)
371.46M
SIRISirius XM Holdings Inc
$ 2.94
(1.38%)
330.66M
AAPLApple Inc
$ 207.49
(-1.04%)
246.38M
NKLANikola Corporation
$ 0.3466
(5.16%)
193.36M

PRQR Discussion

View Posts
Monksdream Monksdream 2 months ago
PRQR under $2
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 2 months ago
added 2.01 hoping for love from LLY, 4bln in milestones.
πŸ‘οΈ0
glenn1919 glenn1919 3 months ago
PRQR.....................................https://stockcharts.com/h-sc/ui?s=PRQR&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
glenn1919 glenn1919 3 months ago
PRQR............................https://stockcharts.com/h-sc/ui?s=PRQR&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
Monksdream Monksdream 4 months ago
PRQR under $2
πŸ‘οΈ0
Monksdream Monksdream 9 months ago
PRQR under $2
πŸ‘οΈ0
AJ Freely AJ Freely 11 months ago
$PRQR - 👆Up 7.3% Pre-Market/ Current Price $1.65
Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets
πŸ‘οΈ0
KeepOn KeepOn 1 year ago
Nice rebound!
πŸ‘οΈ0
Alan Brown Alan Brown 1 year ago
$0.4~
πŸ‘οΈ0
Alan Brown Alan Brown 1 year ago
Ya....
πŸ‘οΈ0
subslover subslover 1 year ago
Eli Lilly sends ProQR 35% higher after expanding RNA editing deal

https://seekingalpha.com/news/3919739-prqr-stock-surges-as-eli-lilly-expands-rna-editing-deal
πŸ‘οΈ0
TommyBoyTrader9460 TommyBoyTrader9460 2 years ago
$PRQR Strong break up the chart..on watch next week

https://stockcharts.com/c-sc/sc?s=PRQR&p=D&b=5&g=0&i=0&r=1668863394516
πŸ‘οΈ0
MADDSTACKER MADDSTACKER 2 years ago
Time for a bounce … I hope :)
πŸ‘οΈ0
KeepOn KeepOn 2 years ago
$4 is the lowest consensus I can find here:
https://etfdailynews.com/news/proqr-therapeutics-nasdaqprqr-pt-lowered-to-8-00/

What say you?

Also, when do we know it stopped dropping?
πŸ‘οΈ0
jaggerxj6 jaggerxj6 2 years ago
....looking for a 80 cent deadcat bounce?????
πŸ‘οΈ0
swampboots swampboots 2 years ago
PRQR holding steady in market colapse odds are for up in 3 days.
πŸ‘οΈ0
swampboots swampboots 2 years ago
PRQR 1.38 start.
πŸ‘οΈ0
stockguard stockguard 2 years ago
ProQR Therapeutics SCHEDULE 13G 02/04/2022
Amended: It`s a boy!!!!!!!!! Really they only missed a 100,000 shares bought by Wellington Management Group LLP that is runs a lot of Vanguard and ETF funds.....
https://www.streetinsider.com/SEC+Filings/Form++SC+13GA+++ProQR+Therapeutics+N.V.++++++++++++++++Filed+by%3A+WELLINGTON+MANAGEMENT+GROUP+LLP/19559743.html
πŸ‘οΈ0
JohnLocke101 JohnLocke101 3 years ago
nm
πŸ‘οΈ0
JohnLocke101 JohnLocke101 3 years ago
Important area here for PRQR in the 8.40ish resistance. Hopefully we can get a volume surge.
πŸ‘οΈ0
JohnLocke101 JohnLocke101 3 years ago
Some Nov/Dec call options with $10 strike traded today.. time for the pps to get up there. Looking stable going into 2022. Q 1/2 will be big.
πŸ‘οΈ0
JohnLocke101 JohnLocke101 3 years ago
Im liking the setup. Come on PRQR, make the move. Bollinger says we’re close.
πŸ‘οΈ0
MADDSTACKER MADDSTACKER 3 years ago
Lilly earnings tomorrow wonder if we get a mention
πŸ‘οΈ0
JohnLocke101 JohnLocke101 3 years ago
Investment Case On ProQR Therapeutics Gets More Enticing
πŸ‘οΈ0
murocman murocman 3 years ago
Looks like the high 7’s are even better! Man somebody took the air out of this balloon today.

Murocman
πŸ‘οΈ0
JohnLocke101 JohnLocke101 3 years ago
Low $8’s is a great place to add, me thinks.
πŸ‘οΈ0
MADDSTACKER MADDSTACKER 3 years ago
You to
πŸ‘οΈ0
JohnLocke101 JohnLocke101 3 years ago
Yep. Editas data validated PRQR. Continued new highs coming.

Good Luck!
πŸ‘οΈ0
MADDSTACKER MADDSTACKER 3 years ago
News out , nice volume
πŸ‘οΈ0
MADDSTACKER MADDSTACKER 3 years ago
Sweet
πŸ‘οΈ0
JohnLocke101 JohnLocke101 3 years ago
I see indications that PRQR is about to make a move up. We’ll see..
πŸ‘οΈ0
MADDSTACKER MADDSTACKER 3 years ago
Mind if I ask what you saw ?
πŸ‘οΈ0
JohnLocke101 JohnLocke101 3 years ago
I think options activity is getting interesting.
πŸ‘οΈ0
MADDSTACKER MADDSTACKER 3 years ago
What do you think of these guys ? Seems like $50 at some point ?
πŸ‘οΈ0
JohnLocke101 JohnLocke101 3 years ago
Oops. Sorry about that.

Oligonucleotides to treat eye disease
πŸ‘οΈ0
MADDSTACKER MADDSTACKER 3 years ago
Is that for prqr ?
πŸ‘οΈ0
JohnLocke101 JohnLocke101 3 years ago
New Patent
πŸ‘οΈ0
MADDSTACKER MADDSTACKER 3 years ago
Anyone else felling a break out coming ?
πŸ‘οΈ0
JohnLocke101 JohnLocke101 3 years ago
Eli Lilly takes 5.6% stake in PRQR according to 13g
πŸ‘οΈ0
JohnLocke101 JohnLocke101 3 years ago
Personally, I think it gets swooped up before then.

Anyone else load up under $8 for another round?

Good Luck!
πŸ‘οΈ0
MADDSTACKER MADDSTACKER 3 years ago
Need some 2023 calls
πŸ‘οΈ0
JohnLocke101 JohnLocke101 3 years ago
Been fun today. Even as quiet as this board is.

Sub 8 now, they’re giving it away, so adding big.. again.

Good Luck!
πŸ‘οΈ0
JohnLocke101 JohnLocke101 3 years ago
β€œQR-421a was observed to be well tolerated at all doses in participants with exon 13 mutations in USH2A. QR-421a demonstrated encouraging evidence of disease stabilization in visual acuity and clinically significant improvements in retinal sensitivity, supported by objective retinal structural imaging data, after a single dose compared with UE and SE. An open-label extension trial is planned to follow up the Stellar trial participants, and 2 Phase 2/3 trials are planned."
πŸ‘οΈ0
JohnLocke101 JohnLocke101 3 years ago
Axiomer
πŸ‘οΈ0
JohnLocke101 JohnLocke101 3 years ago
ProQR Therapeutics teams up with Eli Lilly in potential $1.25B research collaboration
πŸ‘οΈ0
JohnLocke101 JohnLocke101 3 years ago
Added the dip, sub $7
πŸ‘οΈ0
JohnLocke101 JohnLocke101 3 years ago
Vicious little eod rally. Hrmm..
πŸ‘οΈ0
JohnLocke101 JohnLocke101 3 years ago
Looking good leading up to the fireside chat.
πŸ‘οΈ0
JohnLocke101 JohnLocke101 3 years ago
Is it finally time to take the next leg up? Looking promising..
πŸ‘οΈ0
Microlytics Microlytics 3 years ago
Get ready boys and girls, this can rip at any time
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock